A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, brain disorder, central nervous system disorder, epilepsy, epithelial neoplasm, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Phase 1	2026-08-21		NCT04106219

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Eli Lilly and Company	370
Innovative Therapies for Children with Cancer in Europe (ITCC)	1
New Approaches to Neuroblastoma Therapy Consortium	7

17 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alder Hey Children's Hospital	Liverpool	United Kingdom	7
Centre Leon Berard	Lyon	France	2
Children's Hospital Colorado	Aurora	United States	312
Children's Hospital of Philadelphia	Philadelphia	United States	434
Cincinnati Childrens Hospital Medical Center	Cincinnati	United States	10
Dana-Farber Cancer Institute	Boston	United States	68
Hospital Infantil Universitario Niño Jesús	Madrid	Spain	21
Hospital Universitari Vall d'Hebron	Barcelona	Spain	7
Institut Curie	Paris	France	51
Istituto Nazionale dei Tumori	Milan	Italy	4
National Cancer Center Hospital	Chuo-ku	Japan	67
Perth Children's Hospital	Perth	Australia	49
Texas Childrens Hospital	Houston	United States	12
UCSF Medical Center at Mission Bay	San Francisco	United States	16
University of Chicago - Comer Children's Hospital	Chicago	United States	1
Universitätsklinikum Köln	Cologne	Germany	1
UZ Gent	Ghent	Belgium	36